EP4010329 - DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 12.04.2024 Database last updated on 22.08.2024 | |
Former | The patent has been granted Status updated on 05.05.2023 | ||
Former | Grant of patent is intended Status updated on 14.12.2022 | ||
Former | Request for examination was made Status updated on 13.05.2022 | ||
Former | The international publication has been made Status updated on 19.02.2021 | ||
Former | unknown Status updated on 20.08.2020 | Most recent event Tooltip | 12.04.2024 | No opposition filed within time limit | published on 15.05.2024 [2024/20] | Applicant(s) | For all designated states Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | [2022/24] | Inventor(s) | 01 /
BLENCOWE, Peter c/o Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | 02 /
CHARLES, Mark c/o Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | 03 /
EKWURU, Tennyson c/o Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | 04 /
FINCH, Harry c/o Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | 05 /
MCCARRON, Hollie c/o Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | 06 /
HEALD, Robert c/o Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | 07 /
STOCKLEY, Martin c/o Artios Pharma Limited Babraham Hall Babraham Research Campus Cambridge CB22 3AT / GB | [2022/24] | Representative(s) | Sagittarius IP Marlow International Parkway Marlow SL7 1YL / GB | [N/P] |
Former [2022/24] | Gibson, Mark Sagittarius IP Marlow International Parkway Marlow SL7 1YL / GB | Application number, filing date | 20754011.3 | 10.08.2020 | [2022/24] | WO2020GB51901 | Priority number, date | WO2019GB52240 | 09.08.2019 Original published format: PCT/GB2019/052240 | GB20190017863 | 06.12.2019 Original published format: GB 201917863 | [2022/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021028670 | Date: | 18.02.2021 | Language: | EN | [2021/07] | Type: | A1 Application with search report | No.: | EP4010329 | Date: | 15.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.02.2021 takes the place of the publication of the European patent application. | [2022/24] | Type: | B1 Patent specification | No.: | EP4010329 | Date: | 07.06.2023 | Language: | EN | [2023/23] | Type: | B9 Corrected patent specification | No.: | EP4010329 | Date: | 04.10.2023 | [2023/40] | Search report(s) | International search report - published on: | EP | 18.02.2021 | Classification | IPC: | C07D401/04, A61K31/4439, A61P35/00 | [2022/24] | CPC: |
C07D401/04 (EP,IL,KR,US);
A61K31/4439 (KR,US);
A61K45/06 (US);
A61P35/00 (EP,IL,KR);
C07B59/002 (KR);
C07B2200/05 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/24] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | DEUTERIERTE VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG VON KREBS | [2022/24] | English: | DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | [2022/24] | French: | COMPOSÉS DEUTÉRÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER | [2022/24] | Entry into regional phase | 04.03.2022 | National basic fee paid | 04.03.2022 | Designation fee(s) paid | 04.03.2022 | Examination fee paid | Examination procedure | 04.03.2022 | Examination requested [2022/24] | 04.03.2022 | Date on which the examining division has become responsible | 21.09.2022 | Amendment by applicant (claims and/or description) | 15.12.2022 | Communication of intention to grant the patent | 12.04.2023 | Fee for grant paid | 12.04.2023 | Fee for publishing/printing paid | 12.04.2023 | Receipt of the translation of the claim(s) | Opposition(s) | 08.03.2024 | No opposition filed within time limit [2024/20] | Fees paid | Renewal fee | 16.08.2022 | Renewal fee patent year 03 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2013107291 (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-10 * the whole document *; | [A]WO2013107405 (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-10 * the whole document *; | [A]WO2015010297 (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-10 * the whole document *; | [A]WO2018001332 (SHANGHAI HAIHE PHARMACEUTICAL CO LTD [CN], et al) [A] 1-10 * the whole document *; | [A] - JANETA POPOVICI-MULLER ET AL, "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers", ACS MEDICINAL CHEMISTRY LETTERS, US, (20180412), vol. 9, no. 4, doi:10.1021/acsmedchemlett.7b00421, ISSN 1948-5875, pages 300 - 305, XP055630303 [A] 1-10 * the whole document * DOI: http://dx.doi.org/10.1021/acsmedchemlett.7b00421 | by applicant | WO2017062754 | - TRUONG et al., PNAS, (20130000), vol. 110, no. 19, pages 7720 - 7725 | - "UniProtKB", Database accession no. 075417 | - KENT et al., Nature Structural & Molecular Biology, (20150000), vol. 22, no. 3, pages 230 - 237 | - MATEOS-GOMEZ et al., Nature, (20150000), vol. 518, no. 7538, pages 258 - 262 | - WOODDOUBLIE, DNA Repair, (20160000), vol. 44, pages 22 - 32 | - HIGGINS et al., Oncotarget, (20100000), vol. 1, pages 175 - 184 | - LEMEE et al., PNAS, (20100000), vol. 107, no. 30, pages 13390 - 13395 | - KAWAMURA et al., International Journal of Cancer, (20040000), vol. 109, no. 1, pages 9 - 16 | - EMAMI S et al., Biolmpacts, (20180000), vol. 8, no. 4, pages 305 - 320 | - W. DEADY, Syn. Commun., (19770000), vol. 7, pages 509 - 514 | - Drugs of Today, (19830000), vol. 19, no. 9, pages 499 - 538 | - H. BUNDGAARD, Topics in Chemistry, Elsevier, (19850000), pages 306 - 316 | - H. BUNDGAARD, Design of Prodrugs | - T. GREENP. WUTS, Handbook of OrganoPalladium Chemistry for Organic Synthesis, John Wiley and Sons, (20070000), vol. 1 | - R. G. STRICKLY, "Solubilizing Excipients in oral and injectable formulations", Pharmaceutical Research, (20040000), vol. 21, no. 2, pages 201 - 230 | - J. Control. Release, (20030000), vol. 91, no. 1-2, pages 167 - 172 | - SINHA et al., Mol. Cancer Ther., (20060801), vol. 5, page 1909 | - CHIOURIEGELMAN, J. Pharm. Sci., (19710000), vol. 60, pages 1281 - 1300 | - CHOU TCTALALAY P, "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors", Adv Enzyme Regulat, (19840000), vol. 22, doi:10.1016/0065-2571(84)90007-4, pages 27 - 55, XP023796270 DOI: http://dx.doi.org/10.1016/0065-2571(84)90007-4 | - CHEMICAL ABSTRACTS, Database accession no. 22123-14-4 |